Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of two FT218 4.5 g batches in healthy volunteers
NL-OMON44364Active, not recruiting
- Sponsor
- Avadel Pharmaceuticals
- Start
- Aug 2017
- Modality
- Cell Therapies, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of AV001 in narcolepsy (2 arms), sponsored by Avadel Pharmaceuticals. Primary endpoint: Bioequivalence of two FT218 batches at 4.5 g. Started Aug 2017; status: active, not recruiting.
02
Drugs
AV001
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON44364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44364.